Previous 10 | Next 10 |
Antengene submits a New Drug Application ((NDA)) in South Korea for ATG-010 (selinexor, XPOVIO) in combination with low dose dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma (rrMM) and for ATG-010 as monotherapy for treatment of relaps...
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL PR Newswire SHANGHAI and HONG KONG , Jan. 3, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedi...
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy --Oral XPOVIO® Approval as Combination Therapy in Patients with Multi...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). On February 22, 2019, the Federal Dr...
Karyopharm Therapeutics (KPTI) announced that FDA has approved XPOVIO in combination with bortezomib and dexamethasone for patients with multiple myeloma after at least one prior therapy.XPOVIO, a first-in-class, oral Selective Inhibitor of Nuclear Export medicine was earlier approved for adu...
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy -- Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands...
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma NEWTON, Mass. , Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (N...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this event. For further details see: Karyopharm Therapeutics (KPTI) Presents At American Society of Hematology - Slideshow
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting NEWTON, Mass. , Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a comme...
Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting NEWTON, Mass. , Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage p...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...